ESC 365 - A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

HFA Premium Access

A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

Session: ePosters in chronic heart failure - treatment 2

Topic: Treatment

Speaker: Doctor E. Salvioni (Milan, IT)

Event: Heart Failure 2024

Congress Presentation

About the speaker

Doctor Elisabetta Salvioni

Monzino Cardiology Centre, Milan (Italy)

0 follower

6 more presentations in this session

Evaluating the efficacy and safety of beta-3 adrenergic receptor agonists in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials

Speaker: Mr L. Rezende De Freitas (BR)

Assessment of remote patient monitoring in patients with chronic heart failure across four European sites

Speaker: Ms M. Verket (Aachen, DE)

Exploring the relationship between EuroSCORE II and aortic calcification in predicting clinical outcomes following cardiac surgery

Speaker: Ms A. Pacheco (Aveiro, PT)

Assessment of treatment adherence in patients with chronic heart failure using the 8-item Morisky Medication Adherence Scale (MMAS-8)

Speaker: Doctor A. Baigozhina (Astana, KZ)

Sodium reduction with low-sodium umami-flavoured bread in chronic heart failure: a randomized clinical pilot study.

Speaker: Doctor F. Gommans (Nijmegen, NL)

Access the full session

ePosters in chronic heart failure - treatment 2

Speakers: Doctor E. Salvioni, Mr L. Rezende De Freitas, Ms M. Verket, Ms A. Pacheco, Doctor A. Baigozhina...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources